Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update

Although imatinib has dramatically improved major outcomes in patients with chronic myeloid leukemia (CML), there are newer tyrosine kinase inhibitors (TKIs) approved worldwide for the treatment of resistant cases, and two second-generation TKIs (dasatinib, nilotinib) are approved in some nations for treating patients in the upfront setting. Radotinib (IY5511HCL, Supect®) is a novel and selective second-generation BCR-ABL1 TKI, which is currently approved in Korea for the treatment of patients with CML both in the upfront and salvage settings. This review mainly focuses on the clinical potential of radotinib in patients with CML in chronic phase in terms of efficacy and safety.

Download Full-text

Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)

Annals of Hematology ◽

10.1007/s00277-021-04406-1 ◽

2021 ◽

Author(s):

Massimo Breccia ◽

◽

Simone Celant ◽

Pier Paolo Olimpieri ◽

Odoardo M. Olimpieri ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Mortality Rate ◽

Tyrosine Kinase ◽

Retrospective Analysis ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Second Generation ◽

Kinase Inhibitors ◽

Chronic Phase

Download Full-text

Comment on "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"

Haematologica ◽

10.3324/haematol.2014.123232 ◽

2015 ◽

Vol 100 (3) ◽

pp. e120-e121 ◽

Cited By ~ 4

Author(s):

S.-H. Kim ◽

D.-W. Kim

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Kinase Inhibitors ◽

Chronic Phase ◽

Efficacy And Safety

Download Full-text

The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2012.12.005 ◽

2013 ◽

Vol 13 (3) ◽

pp. 302-306 ◽

Cited By ~ 17

Author(s):

Elias Jabbour ◽

Hagop Kantarjian ◽

Hady Ghanem ◽

Susan O'Brien ◽

Alfonso Quintas-Cardama ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Second Generation ◽

Kinase Inhibitors ◽

Chronic Phase ◽

Cytogenetic Response ◽

Complete Cytogenetic Response

Download Full-text

Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system

International Journal of Hematology ◽

10.1007/s12185-019-02613-1 ◽

2019 ◽

Vol 109 (4) ◽

pp. 426-439 ◽

Cited By ~ 9

Author(s):

Masahiro Kizaki ◽

◽

Naoto Takahashi ◽

Noriyoshi Iriyama ◽

Shinichiro Okamoto ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Kinase Inhibitors ◽

Chronic Phase ◽

Target System ◽

Newly Diagnosed ◽

Efficacy And Safety

Download Full-text

Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study

Leukemia Research ◽

10.1016/j.leukres.2018.02.013 ◽

2018 ◽

Vol 67 ◽

pp. 109-115 ◽

Cited By ~ 4

Author(s):

Devendra Hiwase ◽

Peter Tan ◽

James D’Rozario ◽

John Taper ◽

Anthony Powell ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Kinase Inhibitors ◽

Chronic Phase ◽

Efficacy And Safety ◽

Phase Iiib

Download Full-text

First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?

Hematology ◽

10.1182/hematology.2020000108 ◽

2020 ◽

Vol 2020 (1) ◽

pp. 228-236

Author(s):

Vivian G. Oehler

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

First Generation ◽

Second Generation ◽

Kinase Inhibitors ◽

Chronic Phase ◽

First Line ◽

The Impact

Abstract In 2020, for the great majority of patients with chronic phase chronic myeloid leukemia (CML), life expectancy is unaffected by a diagnosis of CML because of the unparalleled efficacy of ABL-targeted tyrosine kinase inhibitors (TKIs) in halting disease progression. A wealth of choices exist for first-line treatment selection, including the first-generation TKI imatinib and the second-generation TKIs bosutinib, dasatinib, and nilotinib. How I select first-line therapy between first-generation and second-generation TKIs is discussed in the context of patient-specific CML disease risk, therapy-related risks, and treatment goals. Although rare, identifying patients with CML at higher risk for disease progression or resistance is important and influences first-line TKI selection. I review the impact of first-generation vs second-generation TKI selection on treatment response and outcomes; the ability to achieve, as well as the timing of, treatment-free remission; and the impact of specific TKIs on longer-term health.

Download Full-text